Phase 2 N=7 Randomized Double-blind Treatment

Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy

CIDP · Chronic Inflammatory Demyelinating Polyneuropathy

Bottom Line

View on ClinicalTrials.gov: NCT00962429 ↗

Enrolled (actual)

Serious AEs

—

Results posted

Aug 2020

Primary outcome: Primary: Muscle Strength

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: lipoic acid (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Oregon Health and Science University
Primary completion: Jan 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Muscle Strength	—	—
SECONDARY Hughes Functional Disability Scale	—	—
SECONDARY Forced Vital Capacity (FVC)	—	—
SECONDARY Motor Nerve Conduction Studies (NCS)	—	—

Summary

The purpose of the study is to examine if alpha lipoic acid is an effective treatment for chronic inflammatory demyelinating polyneuropathy (CIDP).

Eligibility Criteria

Inclusion Criteria

diagnosis of CIDP
on a stable dose of immunotherapy for at least 3 months before enrolling in the study

Exclusion Criteria

myelopathy or evidence of central demyelination
persistent neurological deficits from stroke, CNS trauma, or peripheral neuropathy from other causes (eg, diabetes mellitus, IgM, paraproteinaemia, or uraemic, toxic, or familial neuropathy)
evidence of systemic disease that might cause neuropathy
heart diseases (congestive heart failure or arrhythmia)
pulmonary conditions (asthma or CIPD)
rheumatoid conditions (such as rheumatoid arthritis)
renal failure

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00962429). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.